MelioOne
THE WORLD’S FIRST NON-HORMONAL LOCAL THERAPY FOR MENSTRUAL PAIN
HOW DOES IT WORK?
MelioOne is centered around a proven polymer-based technology that enables slow and localized release directly at the site of origin. The mechanism releases a sustained low dosage of pain medication to prevent and manage ongoing inflammation that is predominantly responsible for the pain. The dosage amount released in 12 months is equivalent to one Ibuprofen 400 pill and prevents systemic side-effects e.g. on the stomach and the kidneys associated with prolonged high dosage oral consumption.
Our IP application has shown us the strength of the concept being the world’s first IUD loaded with pain medication instead of hormonal contraceptives.
DEVELOPMENTAL JOURNEY
MelioOne is in prototyping phase to test out the polymer-technology that enables the low and slow-release mechanism. We are currently on track with timeline projections and working towards the start of Pre-Clinical Trials by the fourth quarter this year. It will not be until 2029 that we can enter the market with a solution that has been proven safe and effective in clinical trials.
INNOVATION BY COMBINING PROVEN TECHNOLOGIES, NSAIDS AND IUDS
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
NSAIDs are highly effective against inflammation. However, prolonged use or high dosages can come with well-known systemic side-effects such as damage to the kidneys, stomach and intestine.
INTRA-UTERINE DEVICES (IUDS)
IUDs have been on the market for contraception for over 30 years and are safe and effective in delivering drug components directly into the uterus. The use of IUDs can come with hormone-related side-effects such as ovarian cysts, feelings of depression, or weight gain. In addition, people with some other medical and cannot use hormonal IUDs. Other non-hormonal IUDs such as copper IUDs may further intensify menstrual pain and can cause heavy menstrual bleeding.